Performant Financial (PFMT) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues increased 15% year-over-year to $29.4 million, with healthcare revenues up 17% to $27.9 million, driven by commercial and government contract growth, especially claims-based services.

• Net loss for Q2 2024 narrowed to $3.0 million, a 25% improvement from the prior year.

• Adjusted EBITDA for Q2 2024 was $0.5 million, $1.8 million higher than the prior year.

• Ten new commercial implementations in Q2, with 20 total in 2024 expected to generate $9 million in annualized revenue at steady state.

• The company continues to focus on expanding technology-enabled healthcare payment integrity services and scaling both government and commercial contracts.

Financial highlights

• Q2 2024 revenues were $29.4 million, with healthcare revenues at $27.9 million and customer care/outsourced services at $1.4 million (down 7% year-over-year).

• Claims-based business revenue reached $13.7 million, up 39–40% year-over-year; eligibility revenues were $14.3 million, up 1%.

• Net loss for Q2 2024 was $3.0 million, with adjusted net loss per diluted share at $(0.03).

• Operating expenses were $32.1 million, up $3 million from Q2 2023, mainly due to scaling, IT, and sales investments.

• Cash and cash equivalents at June 30, 2024 were $10.4 million, up from $7.3 million at year-end 2023.

Outlook and guidance

• 2024 healthcare revenues are guided to $117–$122 million; total company revenues to $124–$129 million.

• Full-year 2024 Adjusted EBITDA is expected to be $4–$5 million.

• Management expects healthcare revenues to continue driving growth as new programs are implemented and existing relationships mature.

• Targeting 20%+ Adjusted EBITDA margin at $150–$160 million in healthcare revenues.

• Financial projections indicate sufficient cash flows from operations to fund ongoing and planned business operations.